CoChat

The Vicious Cycle of Myostatin Signaling in Sarcopenic Obesity: Myostatin Role in Skeletal Muscle Growth, Insulin Signaling and Implications for Clinical Trials

Open access
Consitt, Leslie A., Clark, B.C. · 2018 · The Journal of Frailty & Aging
Cited by 113

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

The age-related loss of skeletal muscle (sarcopenia) is a major health concern as it is associated with physical disability, metabolic impairments, and increased mortality. The coexistence of sarcopenia with obesity, termed 'sarcopenic obesity', contributes to skeletal muscle insulin resistance and the development of type 2 diabetes, a disease prevalent with advancing age. Despite this knowledge, the mechanisms contributing to sarcopenic obesity remain poorly understood, preventing the development of targeted therapeutics. This article will discuss the clinical and physiological consequences of sarcopenic obesity and propose myostatin as a potential candidate contributing to this condition. A special emphasis will be placed on examining the role of myostatin signaling in impairing both skeletal muscle growth and insulin signaling. In addition, the role of myostatin in regulating muscle-to fat cross talk, further exacerbating metabolic dysfunction in the elderly, will be highlighted. Lastly, we discuss how this knowledge has implications for the design of myostatin-inhibitor clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.14283/jfa.2017.33

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 31

  1. Stenholm, 2008, Sarcopenic obesity: definition, cause and consequences, Curr Opin Clin Nutr Metab Care, 11, 693, 10.1097/MCO.0b013e328312c37d · DOI · Paper page
  2. Cauley, 2015, An Overview of Sarcopenic Obesity, Curr Opin Clin Nutr Metab Care, 18, 499
  3. Reaven, 1988, Banting lecture 1988, Role of insulin resistance in human disease, Diabetes, 37, 1595, 10.2337/diab.37.12.1595 · DOI · Paper page
  4. Garber, 2016, No longer going to waste, Nat Biotechnol, 34, 458, 10.1038/nbt.3557 · DOI
  5. Kocsis, 2017, Myostatin propeptide mutation of the hypermuscular Compact mice decreases the formation of myostatin and improves insulin sensitivity, Am J Physiol Endocrinol Metab, 312, 150, 10.1152/ajpendo.00216.2016 · DOI
  6. Sharma, 1999, Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct, J Cell Physiol, 180, 1, 10.1002/(SICI)1097-4652(199907)180:1<1::AID-JCP1>3.0.CO;2-V · DOI · Paper page
  7. Goodman, 2013, Smad3 induces atrogin-1, inhibits mTOR and protein synthesis, and promotes muscle atrophy in vivo, Mol Endocrinol, 27, 1946, 10.1210/me.2013-1194 · DOI · Paper page
  8. Yarasheski, 2002, Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting, J Nutr Health Aging, 6, 343
  9. Leger, 2008, Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation, Rejuvenation Res, 11, 163, 10.1089/rej.2007.0588 · DOI · Paper page
  10. Han, 2011, Serum myostatin levels and grip strength in normal subjects and patients on maintenance haemodialysis, Clin Endocrinol (Oxf), 75, 857, 10.1111/j.1365-2265.2011.04120.x · DOI · Paper page
  11. Patel, 2014, Lean mass, muscle strength and gene expression in community dwelling older men: findings from the Hertfordshire Sarcopenia Study (HSS), Calcif Tissue Int, 95, 308, 10.1007/s00223-014-9894-z · DOI
  12. Tay, 2015, Sex-specific differences in risk factors for sarcopenia amongst community-dwelling older adults, Age (Dordr), 37, 121, 10.1007/s11357-015-9860-3 · DOI · Paper page
  13. Hofmann, 2015, Serum concentrations of insulinlike growth factor-1, members of the TGF-beta superfamily and follistatin do not reflect different stages of dynapenia and sarcopenia in elderly women, Exp Gerontol, 64, 35, 10.1016/j.exger.2015.02.008 · DOI
  14. Ratkevicius, 2011, Serum concentrations of myostatin and myostatin-interacting proteins do not differ between young and sarcopenic elderly men, J Gerontol A Biol Sci Med Sci, 66, 620, 10.1093/gerona/glr025 · DOI · Paper page
  15. Borkan, 1983, Age changes in body composition revealed by computed tomography, J Gerontol, 38, 673, 10.1093/geronj/38.6.673 · DOI · Paper page
  16. Consitt, 2013, Impairments in site-specific AS160 phosphorylation and effects of exercise training, Diabetes, 62, 3437, 10.2337/db13-0229 · DOI · Paper page
  17. Ryan, 2013, Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults, Obesity (Silver Spring), 21, 1350, 10.1002/oby.20216 · DOI · Paper page
  18. Palsgaard, 2009, Gene expression in skeletal muscle biopsies from people with type 2 diabetes and relatives: differential regulation of insulin signaling pathways, PLoS One, 4, 6575, 10.1371/journal.pone.0006575 · DOI · Paper page
  19. Milan, 2004, Changes in muscle myostatin expression in obese subjects after weight loss, J Clin Endocrinol Metab, 89, 2724, 10.1210/jc.2003-032047 · DOI · Paper page
  20. Morissette, 2009, Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt, Am J Physiol Cell Physiol, 297, C1124, 10.1152/ajpcell.00043.2009 · DOI · Paper page
  21. Tang, 2014, A prepared anti-MSTN polyclonal antibody reverses insulin resistance of diet-induced obese rats via regulation of PI3K/Akt/mTOR&FoxO1 signal pathways, Biotechnol Lett, 36, 2417, 10.1007/s10529-014-1617-z · DOI
  22. Consitt, 2010, Peroxisome proliferator-activated receptor-gamma coactivator-1alpha overexpression increases lipid oxidation in myocytes from extremely obese individuals, Diabetes, 59, 1407, 10.2337/db09-1704 · DOI · Paper page
  23. Pauly, 2015, Combined Strategies for Maintaining Skeletal Muscle Mass and Function in Aging: Myostatin Inactivation and AICAR-Associated Oxidative Metabolism Induction, J Gerontol A Biol Sci Med Sci, 70, 1077, 10.1093/gerona/glu147 · DOI
  24. Takahashi, 2014, Myostatin alters glucose transporter-4 (GLUT4) expression in bovine skeletal muscles and myoblasts isolated from double-muscled (DM) and normal-muscled (NM) Japanese shorthorn cattle, Domest Anim Endocrinol, 48, 62, 10.1016/j.domaniend.2014.01.007 · DOI
  25. Rodriguez, 2017, Crosstalk between adipokines and myokines in fat browning, Acta Physiol (Oxf), 219, 362, 10.1111/apha.12686 · DOI · Paper page
  26. Cinti, 2012, The adipose organ at a glance, Dis Model Mech, 5, 588, 10.1242/dmm.009662 · DOI · Paper page
  27. Yoneshiro, 2011, Age-related decrease in coldactivated brown adipose tissue and accumulation of body fat in healthy humans, Obesity (Silver Spring), 19, 1755, 10.1038/oby.2011.125 · DOI · Paper page
  28. Yang, 2003, Reduced expression of FOXC2 and brown adipogenic genes in human subjects with insulin resistance, Obes Res, 11, 1182, 10.1038/oby.2003.163 · DOI · Paper page
  29. Chondronikola, 2014, Brown adipose tissue improves whole-body glucose homeostasis and insulin sensitivity in humans, Diabetes, 63, 4089, 10.2337/db14-0746 · DOI · Paper page
  30. Choi, 2011, Increased energy expenditure and leptin sensitivity account for low fat mass in myostatin-deficient mice, Am J Physiol Endocrinol Metab, 300, 1031, 10.1152/ajpendo.00656.2010 · DOI · Paper page
  31. Kalinkovich, 2015, Sarcopenia—The search for emerging biomarkers, Ageing Res Rev, 22, 58, 10.1016/j.arr.2015.05.001 · DOI · Paper page

Cited by

See all 113

Metadata

Authors
Consitt, L. A., & Clark, B. C.
Venue
The Journal of Frailty & Aging
Publisher
Elsevier BV
Published
2018-01
Volume
7
Issue
1
Pages
21-27
ISSN
2260-1341 (ISSN-L)
OpenAlex
W2897010519
Cited by
113
References
22
FWCI
3.37
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.